Choroidal thickness predicts axial elongation in adults with high myopia
Many adults with high myopia continue to experience axial elongation, yet no validated tool exists to identify who is most likely to progress. This prospective study investigated predictors of continued axial elongation in adults with high myopia and developed a simplified prediction model based on age and choroidal thickness.
Paper title: Prediction of axial elongation in adults with high myopia: the Wenzhou High Myopia Cohort Study.
Authors: Wang Y(1), Rui X(1), Sun Y(1), Li Y, Ding S(1), Zhang Z(1), Lu J(1), Wu M(1), Qu J(1), Zhou X(2,3), Wu H(4)
- Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), State Key Laboratory of Eye Health, National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), State Key Laboratory of Eye Health, National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China. zxt@mail.eye.ac.cn.
- State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zxt@mail.eye.ac.cn.
- Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), State Key Laboratory of Eye Health, National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China. wuhao@eye.ac.cn
Date: Jun 2026
References: Wang Y, Rui X, Sun Y, Li Y, Ding S, Zhang Z, Lu J, Wu M, Qu J, Zhou X, Wu H. Prediction of axial elongation in adults with high myopia: the Wenzhou High Myopia Cohort Study. Eye Vis (Lond). 2026 Jun 22
Summary
Axial elongation can continue into adulthood in some people with high myopia, increasing the risk of vision-threatening complications. While several potential risk factors have been identified, their ability to predict future axial elongation remains uncertain. This study investigated whether ocular and demographic factors could be used to identify adults with high myopia at greater risk of continued axial elongation.
This prospective cohort study included 1,025 eyes from 532 adults aged 18 to 60 years with high myopia from the Wenzhou High Myopia Cohort Study in China. Baseline demographic and ocular measurements included axial length, refraction and OCT-derived choroidal measurements, with axial length measured again after two years. The researchers evaluated nine potential predictors and developed prediction models for rapid axial elongation, defined as an increase in axial length of at least 0.10 mm over two years.
Key study outcomes were as follows
- Mean axial elongation was 0.020 mm per year, with 25% of eyes meeting the study definition of rapid axial elongation of at least 0.10 mm over two years.
- Choroidal thickness (ChT) was the strongest individual predictor of rapid axial elongation, followed by age. Thinner ChT and younger age were associated with greater risk, while baseline axial length and refractive error showed lower individual predictive ability.
- A simplified model combining ChT and age performed similarly to the full six-variable model, which included age, sex, axial length, visual acuity, ChT and choroidal vascularity index. This remained consistent when the model was internally tested for reliability.
- The relationship between ChT and axial elongation was non-linear. Below approximately 138 μm, thinner choroids were associated with faster axial elongation.
- The modelled ChT threshold varied substantially with age, decreasing from 187 μm at age 20 to 29 μm at age 60, indicating that ChT needs to be considered in relation to age rather than as a single threshold across adulthood.
What does this mean for my practice?
Choroidal thickness (ChT) may provide additional information when assessing adults with high myopia for risk of continued axial elongation. In this cohort, ChT was a stronger individual predictor than age, refractive error or axial length, while a model combining only ChT and age performed similarly to the more complex six-variable model.
The modelled ChT threshold associated with increased risk decreased with age, suggesting that ChT needs to be considered alongside patient age rather than using a single predictive cut-off across adulthood.
For eyecare practitioners who have access to OCT choroidal measurements, these findings suggest that ChT and age could help identify adults with high myopia who may benefit from closer monitoring. However, the model has so far only been tested within the study population, so the proposed thresholds should not yet be considered established clinical cut-offs.
What do we still need to learn
The prediction model was developed and internally tested within a single Chinese cohort, so external validation is needed to establish whether it performs similarly in other populations and clinical settings.
Most participants had relatively healthy fundii or early-stage myopic maculopathy, so it is uncertain whether the model applies to adults with more advanced myopic macular changes. Additional factors, including genetic variation, may also improve prediction beyond the variables evaluated in this study.
The study does not establish whether identifying adults at higher risk and changing their monitoring or management improves clinical outcomes. Longer-term studies would be needed to determine whether risk-based management can help prevent sight-threatening complications.
Abstract
Background: Identifying individuals at high risk of axial elongation is crucial for managing adults with high myopia, as further elongation substantially increases the risk of vision-threatening complications. This study aimed to identify the optimal predictors for axial elongation in this population.
Methods: This prospective cohort study enrolled 1025 eyes from 532 adults with high myopia (18–60 years). We evaluated the predictive performance of nine candidate variables for rapid axial elongation, defined as a 2-year axial elongation of at least 0.10 mm. Predictors were selected using bidirectional stepwise regression. Model discrimination was assessed using the area under the receiver operating characteristic curve (AUC), and the incremental value of the new model was quantified using integrated discrimination improvement (IDI).
Results: The mean annual axial elongation rate was 0.020 ± 0.051 mm/year, and 24.78% of eyes developed rapid axial elongation. Stepwise regression constructed a full model (AUC = 0.811) including six predictors—age, sex, axial length, best-corrected visual acuity, choroidal thickness (ChT), and vascularity index. ChT showed the highest individual discriminative ability (AUC = 0.728), followed by age (AUC = 0.666). Removing age or ChT from the full model reduced the AUCs to 0.735 and 0.753, respectively (both P < 0.001), with IDIs of − 0.116 and − 0.095 (both P < 0.001). In contrast, excluding sex only resulted in an IDI of − 0.008 (P = 0.032). Simplified models combining age and ChT, with or without sex, showed discrimination comparable to that of the full model, with only modest reductions in predictive performance (IDIs: − 0.028 and − 0.033, respectively; both P < 0.05). In the bivariate model, the predictive cut-off of ChT decreased progressively with age, ranging from 187 µm at age 20 to 29 µm at age 60. The results remained consistent in sensitivity analyses using alternative axial elongation definitions (0.05 mm and 0.15 mm). Nonlinear relationship analyses revealed that thinner choroids were associated with faster axial elongation rate only below an inflection point.
Conclusions: ChT and age are the optimal predictors for axial elongation in adults with high myopia. These findings establish their dominant role in personalized management and support further investigation into choroidal architecture to guide proactive, choroid-centered strategies.
Enormous thanks to our visionary sponsors
Myopia Profile’s growth into a world leading platform has been made possible through the support of our visionary sponsors, who share our mission to improve children’s vision care worldwide. Click on their logos to learn about how these companies are innovating and developing resources with us to support you in managing your patients with myopia.